The FDA has granted Fast Track Designation to CTIM-76, a claudin-6 (CLDN6) x CD3 T cell engaging bispecific antibody, for the ...
A new technique may reprogram immune cells inside the body, offering faster, simpler, and more accessible cancer treatment.